DRAXIS to Present at the 2007 UBS Global Life Sciences Conference
18 Septembre 2007 - 1:00PM
PR Newswire (US)
MISSISSAUGA, ON, Sept. 18 /PRNewswire-FirstCall/ -- DRAXIS Health
Inc. (TSX: DAX) (NASDAQ:DRAX) will participate in the 2007 UBS
Global Life Sciences Conference, which is being held in New York,
NY, from September 24 - 27, 2007 at The Grand Hyatt Hotel. Mr. Dan
Brazier, Chief Operating Officer, is scheduled to present on Monday
September 24, at 1:00 p.m. ET. Investors can listen to a live audio
webcast of the DRAXIS presentation or can access the replay for 30
days following the conference at DRAXIS website at
http://www.draxis.com/ About DRAXIS Health Inc.: DRAXIS Health,
through its wholly owned operating subsidiary, DRAXIS Specialty
Pharmaceuticals Inc., provides products in three categories:
sterile products, non-sterile products and radiopharmaceuticals.
Sterile products include liquid and freeze-dried (lyophilized)
injectables plus sterile ointments and creams. Non-sterile products
are produced as solid oral and semi-solid dosage forms.
Radiopharmaceuticals are used for both therapeutic and diagnostic
molecular imaging applications. Pharmaceutical contract
manufacturing services are provided through the DRAXIS Pharma
division and radiopharmaceuticals are developed, produced, and sold
through the DRAXIMAGE division. DRAXIS employs approximately 500
staff in its Montreal facility. For additional information please
visit http://www.draxis.com/ Caution Concerning Forward-Looking
Statements This news release contains forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933, as
amended (the "Securities Act") and Section 21E of the Securities
Exchange Act of 1934, as amended (the "Exchange Act") and as
contemplated under other applicable securities legislation. These
statements can be identified by the use of forward-looking
terminology such as "may," "will," "expect," "anticipate,"
"estimate," "continue," "plan," "intend," "believe" or other
similar words. These statements discuss future expectations
concerning results of operations or financial condition or provide
other forward-looking information. Our actual results, performance
or achievements could be significantly different from the results
expressed in, or implied by, those forward-looking statements. You
should not place undue reliance on any forward-looking statement,
which speaks only as of the date made. These statements are not
guarantees of future performance. By their nature, forward-looking
statements involve numerous assumptions, known and unknown risks,
uncertainties and other factors that may cause the actual results
or performance of the Company to be materially different from such
statements or from any future results or performance implied
thereby. Factors that could cause the Company's results or
performance to differ materially from a conclusion, forecast or
projection in the forward-looking statements include, but are not
limited to: - the achievement of desired clinical trial results
related to the Company's pipeline products; - timely regulatory
approval of the Company's products; - the ability to comply with
regulatory requirements applicable to the manufacture and marketing
of the Company's products; - the Company's ability to obtain and
enforce effective patents; - the non-infringement of third party
patents or proprietary rights by the Company and its products; -
factors beyond our control that could cause interruptions in our
operations in our single manufacturing facility (including, without
limitation, material equipment breakdowns); - reimbursement
policies related to health care; - the establishment and
maintenance of strategic collaborative and commercial
relationships; - the Company's dependence on a small number of key
customers; - the disclosure of confidential information by our
collaborators, employees or consultants; - the preservation of
healthy working relationships with the Company's union and
employees; - the Company's ability to grow the business; - the
fluctuation of our financial results and exchange and interest rate
fluctuations; - the adaptation to changing technologies; - the loss
of key personnel; - the avoidance of product liability claims; -
the loss incurred if current lawsuits against us succeed; - the
volatility of the price of our common shares; - market acceptance
of the Company's products; and - the risks described in "Item 3.
Key Information - Risk Factors" in the Annual Report Form 20-F
filed by the Company with the United States Securities and Exchange
Commission and which is also filed as the Company's Annual
Information Form with Canadian securities regulators. For
additional information with respect to certain of these and other
factors, and relating to the Company generally, reference is made
to the Company's most recent filings with the United States
Securities and Exchange Commission (available on EDGAR at
http://www.sec.gov/) and the filings made by the Company with
Canadian securities regulators (available on SEDAR at
http://www.sedar.com/). The forward-looking statements contained in
this new release represent the Company's expectations as at
September 17, 2007. Unless otherwise required by applicable
securities laws, the Company disclaims any intention or obligation
to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise. DATASOURCE:
DRAXIS Health Inc. CONTACT: DRAXIS Health Inc., Jerry Ormiston,
Executive Director, Investor Relations, Phone: 1-877-441-1984
Copyright
Draxis Health (MM) (NASDAQ:DRAX)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Draxis Health (MM) (NASDAQ:DRAX)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Draxis Health (MM) (NASDAQ): 0 recent articles
Plus d'articles sur Draxis Health Inc. - Common Shares (MM)